Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept

Methods 190 JIA patients were treated with abatacept for 4 months in an open-label lead-in period (Period A). ACR Pedi 30 responders (n = 123) were then randomized 1:1 to receive abatacept or placebo for 6 months in a double-blind withdrawal period (Period B). Activity participation for the child and the parents were assessed, along with clinical and quality of life (QOL) parameters. Mean change from baseline in each period was analyzed, and the two treatment groups were compared.